Liraglutide (Saxenda for obesity, Victoza for diabetes) is the first-generation once-daily GLP-1 receptor agonist now overshadowed by once-weekly semaglutide and tirzepatide. It still surfaces in three current storylines.
First, regulation. The FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list folds liraglutide into the broader compounding crackdown. The Federal Register notice (published May 1) found no clinical need for outsourcing facilities to compound any of the three from bulk substances; comments close June 29.
Second, neurology. The ELAD Phase 2b trial — a multicenter, randomized, placebo-controlled study of liraglutide in 204 mild-to-moderate Alzheimer's patients, published in Nature Medicine — keeps the GLP-1-in-dementia conversation alive even as semaglutide trials accumulate.
Third, real-world tail. The May 2026 ECO analysis of 89,718 patients found 6.9% were on liraglutide — small versus 75.6% on semaglutide and 17.5% on tirzepatide, but enough to anchor pre-Wegovy comparator data. See [[semaglutide]], [[tirzepatide]], and [[503b-bulks-list]].
The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026 after a Federal Register-extended deadline from the original June 29 cutoff. The FDA's underlying finding: no clinical need for FDA-registered outsourcing facilities to compound the three GLP-1 molecules from bulk drug substances. Section 503B outsourcing facilities are the FDA-registered large-scale compounding manufacturers (as distinct from state-licensed 503A pharmacies that compound for individual patient prescriptions). Finalization of the proposed rule would close the last legal pathway for large-scale FDA-registered 503B outsourcing facility compounding of the branded GLP-1 molecules, following the December 2024 semaglutide shortage resolution and February 2025 tirzepatide shortage resolution that ended the shortage-based compounding pathway. FDA rulemaking to finalize the exclusion after comment-period close typically takes 3-9 months depending on the volume and substance of received comments. Telehealth platforms including Hims & Hers Health (NYSE: HIMS) and LifeMD have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure. FDA Adverse Event Reporting System (FAERS) data as of the July 2026 safety statement: 990 adverse events linked to compounded semaglutide, over 730 for compounded tirzepatide.
The FDA public comment period on the April 30, 2026 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the Section 503B Bulks List closed Thursday July 30, 2026. If the FDA finalizes the rule, large-scale FDA-registered 503B outsourcing facilities will no longer be able to legally prepare compounded semaglutide, tirzepatide, or liraglutide once the shortage-based compounding pathway has fully closed. The 503B exclusion is the parallel-track regulatory action to the July 23-24 PCAC vote on the 7 research peptides for the 503A Bulks List. Where 503A operates under state pharmacy board licensure for individual-patient prescriptions, 503B operates under FDA registration for bulk manufacturing at outsourcing facilities. The 503A vote broadened access to 6 of 7 research peptides (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon; DSIP rejected). The 503B exclusion narrows access for the branded GLP-1 franchise. Both actions require FDA rulemaking to formalize, with typical timelines of 6-18 months from the date the agency decides to act. Telehealth companies including Hims & Hers Health (NYSE: HIMS) and LifeMD (NASDAQ: LFMD) have already migrated to branded supply through Novo Nordisk and Eli Lilly commercial channels ahead of the expected 503B closure.
Australia's Therapeutics Goods Administration (TGA) issued a class-wide product warning update Saturday July 25, 2026 for GLP-1 receptor agonists on non-arteritic anterior ischaemic optic neuropathy (NAION), a rare but severe form of eye disorder that may result in permanent visual impairment including blindness. No treatment has been shown to improve visual acuity outcomes after NAION onset. The label update applies across all five GLP-1 RA products currently marketed in Australia: Trulicity (dulaglutide, Eli Lilly), Ozempic (semaglutide, Novo Nordisk), Wegovy (semaglutide, Novo Nordisk), Mounjaro (tirzepatide, Eli Lilly), and Saxenda (liraglutide, Novo Nordisk). The Advisory Committee on Medicines concluded that the current evidence supports the signal for semaglutide but not for dulaglutide or tirzepatide. A search of the Australian Database of Adverse Event Notifications (DAEN) found 36 cases of optic ischaemic neuropathy with GLP-1 RAs, including 23 for semaglutide, 10 for tirzepatide, and 3 for liraglutide. Patient guidance advises seeking urgent medical attention for any sudden vision loss including partial loss of vision. The Australian action follows the UK MHRA Drug Safety Update on semaglutide and NAION issued February 5, 2026.
The FDA's public comment window on the proposed permanent exclusion of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list closes Monday June 29, 2026 at 11:59 PM ET. The proposal (Federal Register notice May 1, docket 2026-08552) cited 'no clinical need' for outsourcing facilities to compound these drugs from bulk substances given commercial availability of the branded products. The final-comment filers split along expected lines. National Community Pharmacists Association (NCPA) and Alliance for Pharmacy Compounding (APC) argue for retention given continuing patient-access gaps for high-cost branded supply, particularly in rural and underserved markets where Hims & Hers and LifeMD telehealth penetration is lower. Partnership for Safe Medicines and the FDA's CDER drug safety arm support the exclusion, citing more than 455 adverse event reports linked to compounded semaglutide and 320+ reports tied to compounded tirzepatide as of early 2025, with a large fraction involving patient self-dosing errors from multidose vials. The FDA will publish its final determination in the Federal Register within several months of comment closure. Once finalized, large-scale compounded GLP-1 distribution through 503B outsourcing facilities ends; patient-specific 503A compounding may continue under narrow circumstances.
The FDA's public comment window on the proposed permanent exclusion of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) from the 503B bulks list closes Monday June 29, 2026, one day from this Sunday digest. The FDA proposed the exclusion on April 30 via a Federal Register notice published May 1 (docket 2026-08552), citing 'no clinical need' for outsourcing facilities to compound these drugs from bulk substances given commercial availability of the branded products. Once the comment window closes and the FDA finalizes the determination, large-scale compounded GLP-1 distribution through 503B outsourcing facilities effectively ends. Patient-specific compounding through 503A pharmacies may continue under narrow circumstances (drug-shortage triggers, patient-specific clinical needs documented by the prescribing physician), but the bulk-compounding channel that supplied the 2022-2024 shortage-era compounded GLP-1 wave gets formally closed. The Partnership for Safe Medicines and FDA's CDER drug safety arm welcomed the proposal; compounding-pharmacy industry groups (APC, OFA) filed comments arguing for retention given continuing patient-access gaps for high-cost branded supply.
An analysis of 60,000+ Americans with type 2 diabetes, presented at ENDO 2026 by Sainikhil Sontha (Boston University School of Public Health) and published in the Endocrine Society press release stream, found that 40% of GLP-1 users discontinued the medication within 12 months and roughly 60% had stopped by the end of two years. Among those who stopped, 41.5% restarted within a year and 58% within two years. Discontinuation was higher among Medicaid/Medicare beneficiaries, Black patients, and patients with documented nausea or GI side effects (37% of stoppers). Newer-generation tirzepatide users were 41% less likely to discontinue than liraglutide users, and patients whose first GLP-1 was prescribed by an endocrinologist were 10% less likely to stop. The data complement the Cleveland Clinic 8,000-patient real-world finding (March) and the eClinicalMedicine Budini meta-regression on weight-regain trajectory, sharpening the picture of how GLP-1 therapy churn actually unfolds in US insurance-claims populations.
The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list enters its final two weeks of public comment on June 15. The 60-day comment window closes June 29, after which the agency will weigh comments and issue final rulemaking. Once finalized, the rule will prohibit 503B outsourcing facilities from bulk-compounding these GLP-1 molecules under any circumstance, including future shortage designation. The 503A pathway through licensed pharmacies remains intact ahead of the July 23-24 PCAC peptide-compounding advisory meeting, but the trajectory for large-scale GLP-1 compounding is fixed. Telehealth platforms (Hims & Hers, LifeMD, others) had already migrated to branded supply via Novo and Lilly partnerships since Q1 2026.
The FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list approaches its June 29 comment-window close. Once finalized, the rule effectively bars large-scale compounding of these GLP-1s under any clinical-need exception, accelerating the wind-down already underway among compounders (ProRx, BPI Labs, the Hims-affiliated manufacturer Medisource). Compounded GLP-1 telehealth platforms have largely pivoted to branded-drug fulfillment or microdose protocols, with the regulatory cliff at three weeks out.
An ECO 2026 analysis covered May 18 by ScienceDaily examined 89,718 patients starting GLP-1 therapy — 75.6% semaglutide, 17.5% tirzepatide, 6.9% liraglutide — and stratified BMI change at year one. In the first year, 27% reduced BMI by less than 5%, 22.4% by 5-10%, 14.1% by 10-15%, and 15.8% by ≥15%, while 20.8% actually gained weight. Greater weight loss correlated with larger reductions in obesity-related risk endpoints; patients who gained weight after starting treatment faced worse health outcomes than untreated comparators in several measures.
The FDA announced a proposal on April 30 to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, finding no clinical need for large-scale compounding now that branded supply has stabilized. Commissioner Marty Makary said outsourcing facilities cannot lawfully compound from bulk substances when FDA-approved drugs are available unless a clear clinical need exists. Public comments are open through June 29, 2026. The proposal targets 503B outsourcing facilities only and does not directly affect 503A patient-specific compounding, but it forecloses the largest legal pathway for branded-active GLP-1 compounding.
The ELAD trial — a multicenter, randomized, double-blind, placebo-controlled Phase 2b study of liraglutide in 204 mild-to-moderate Alzheimer's disease participants — published in Nature Medicine (online December 2025) continues to drive clinical-research discussions about GLP-1s in neurodegeneration. Coming after the Phase 3 EVOKE trials' negative cognition results, ELAD's intermediate-stage findings are being parsed for endpoints, mechanisms, and biomarker patterns that may guide future trial design in this contested indication.